Toxicological profile	NTIS order No.	CAS No.
THIOCYANATE		000302–04–5
POTASSIUM CYANIDE		000151–50–8
CALCIUM CYANIDE		000592–01–8
COPPER(I) CYANIDE		000544–92–3
POTASSIUM SILVER CYANIDE		000506–61–6
CYANOGEN		000460–19–5
CYANOGEN CHLORIDE		000506–77–4
6. DICHLORVOS	PB98–101124	000062–73–7
7. NICKEL (UPDATE)	PB98–101199	007440–02–0
NICKEL CHLORIDE		007718–54–9
NICKEL OXIDE		001313–99–1
NICKEL SULFATE		007786–81–4
NICKEL SUBSULFIDE		012035–72–2
NICKEL ACETATE		000373–02–4
NICKEL NITRATE		013138–45–9
8. POLYCHLORINATED BIPHENYLS (UPDATE)	PB98–101173	001336–36–3
AROCLOR 1016		012674–11–2
AROCLOR 1221		011104–28–2
AROCLOR 1232		011141–16–5
AROCLOR 1242		053469–21–9
AROCLOR 1248		012672–29–6
AROCLOR 1254		011097–69–1
AROCLOR 1260		011096–82–5
AROCLOR 1262		037324–23–5
AROCLOR 1268		011100–14–4
9. TETRACHLOROETHYLENE (UPDATE)	PB98–101181	000127–18–4
10. TRICHLOROETHYLENE (UPDATE)	PB98–101165	000079–01–6
11. VINYL CHLORIDE (UPDATE)	PB98–101132	000075–01–4

Dated: December 17, 1997.

Georgi Jones,

Director, Office of Policy and External Affairs, Agency for Toxic Substances and Disease Registry.

[FR Doc. 97–33507 Filed 12–23–97; 8:45 am]

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency For Toxic Substances and Disease Registry

[ATSDR–132]

Availability of Final Toxicological Profiles

AGENCY: Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (HHS).

ACTION: Notice of availability.

SUMMARY: This notice announces the availability of nine final toxicological profiles on unregulated hazardous substances prepared by ATSDR for the Department of Defense.

FOR FURTHER INFORMATION CONTACT: Ms. Loretta Norman, Division of Toxicology, Agency for Toxic Substances and Disease Registry, Mailstop E–29, 1600 Clifton Road, NE., Atlanta, Georgia 30333, telephone (404) 639–6322.

SUPPLEMENTARY INFORMATION: The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Pub. L. 99–499) amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (Superfund) or CERCLA. Section 211 of SARA also amended Title 10 of the U.S. Code, creating the Defense Environmental Restoration Program. Section 2704(a) and (b) of Title 10 of the U.S. Code directs the Secretary of Defense to notify the Secretary of Health and Human Services of not less than 25 of the most commonly found, unregulated hazardous substances at defense facilities. The Secretary of HHS shall take necessary steps to ensure the timely preparation of toxicological profiles of these substances. Each profile includes an examination, summary and interpretation of available toxicological information and epidemiological evaluations. This information and these data are used to ascertain the levels of significant human exposure for the substance and the associated health effects. The profiles include a determination of whether adequate information on the health effects of each substance is available or under development. When adequate information is not available, in cooperation with the National Toxicology Program (NTP), ATSDR may plan a program of research designed to determine these health effects.

Notice of the availability of nine new draft toxicological profiles for public review and comment was published in the **Federal Register** on October 18, 1994 (59 FR 52549), with notice of a 90-day public comment period for each profile, starting from the actual release date. Following the close of each comment period, chemical-specific comments were addressed, and where appropriate, changes were incorporated into each profile.

The public comments, the classification of and response to those comments, and other data submitted in response to the **Federal Register** notice bear the docket control number ATSDR–86. This material is available for public inspection at the Division of Toxicology, Agency for Toxic Substances and Disease Registry, Building 4, Suite 2400, Executive Park Drive, Atlanta, Georgia (not a mailing address), between 8 a.m. and 4:30 p.m., Monday through Friday, except legal holidays.

Availability

This notice announces the availability of nine final toxicological profiles for the Department of Defense. The following toxicological profiles are now available through the U.S. Department of Commerce, National Technical Information Service (NTIS), 5285 Port Royal Road, Springfield, Virginia 22161, telephone 1–800–553–6847. There is a charge for these profiles as determined by NTIS.

Toxicological profile	NTIS order No.	CAS No.
1. Di–N–OCTYLPHTHALATE	PB98–101033	000117–84–0
2. ETHYLENE GLYCOL/	PB98–101108	000107–21–1
PROPYLENE GLYCOL		000057–55–6
3. HEXACHLOROETHANE	PB98–101041	000067–72–1
4. HMX	PB98–101058	002691–41–0
5. HYDRAULIC FLUIDS	PB98–101066	VARIOUS
6. HYDRAZINES	PB98–101025	000302–01–2
1,1-DIMETHYLHYDRAZINE		000057–14–7
1,2-DIMETHYLHYDRAZINE		000540–73–8
DIMETHYLHYDRAZINE		030260–66–3
7. MINERAL-BASED CRANKCASE OIL	PB98–101066	008002–05–9
8. TITANIUM TETRACHLORIDE	PB98–101074	007550–45–0
9. WHITE PHOSPHORUS	PB98–101082	007723–14–0

Dated: December 17, 1997.

Georgi Jones,

Director, Office of Policy and External Affairs, Agency for Toxic Substances and Disease Registry.

[FR Doc. 97–33508 Filed 12–23–97; 8:45 am]

BILLING CODE 4163–70–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Vaccine Advisory Committee (NVAC), Subcommittee on Future Vaccines, Subcommittee on Immunization Coverage, and Subcommittee on Vaccine Safety: Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following Federal advisory committee meetings.

Name: National Vaccine Advisory Committee (NVAC).

Times and Dates: 9 a.m.–2 p.m., January 12, 1998. 8:30 a.m.–1:15 p.m., January 13, 1998.

Place: Hubert H. Humphrey Building, Room 800, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Notice: In the interest of security, the Department has instituted stringent procedures for entrance to the Hubert H. Humphrey Building by non-government employees. Thus, persons without a government identification card should plan to arrive at the building each day either between 8 and 8:30 a.m. or 12:30 and 1 p.m. so they can be escorted to the meeting. Entrance to the meeting at other times during the day cannot be assured.

Purpose: This committee advises and makes recommendations to the Director of the National Vaccine Program on matters related to the Program responsibilities.

Matters To Be Discussed: Agenda items will include updates on the National Vaccine Program Office (NVPO) activities; the National Vaccine Plan and NVAC's role in defining priorities for action; unmet needs funding—past, present and future; adult immunization: report of the workgroup; use of non-traditional sites for adult immunization; influenza: a growing need for pandemic preparedness; and a discussion on vaccines for international travel.

In addition, there will be updates on welfare reform and effects on immunization; moving towards a Department of Health and Human Services' vaccine safety action plan; work group on philosophical exemptions—final report; the presidential initiative on immunization registries; global use of critically needed vaccines—strategies to consider. There will be reports from the Subcommittee on Immunization Coverage, Subcommittee on Future Vaccines, and Subcommittee on Vaccine Safety.

Name: Subcommittee on Immunization Coverage.

Time and Date: 2 p.m.–5 p.m., January 12, 1998.

Place: Hubert H. Humphrey Building, Room 423A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee will identify and propose solutions that provide a multifaceted and holistic approach to reducing barriers that result in low immunization coverage for children.

Matters To Be Discussed: This subcommittee will hold a discussion on the review of recommendations from the document, ''Strategies to Sustain Immunization Coverage,'' and the finalization of those recommendations.

Name: Subcommittee on Future Vaccines.

Time and Date: 2 p.m.–5 p.m., January 12, 1998.

Place: Hubert H. Humphrey Building, Room 405A, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: The Subcommittee on Future Vaccines will develop policy options and guide national activities which will lead to accelerated development, licensure, and best use of new vaccines in the simplest possible immunization schedules.

Matters To Be Discussed: This subcommittee will hold discussions regarding the continued evaluation of methods to remove barriers to development, licensure and use of safe and effective new vaccines; combination vaccines, strategic options; and defining future vaccines policy issues for travelers' vaccines.

Name: Subcommittee on Vaccine Safety.

Time and Date: 2 p.m.–5 p.m., January 12, 1998.

Place: Hubert H. Humphrey Building, Room 800, 200 Independence Avenue, SW, Washington, DC 20201.

Status: Open to the public, limited only by the space available.

Purpose: This subcommittee will review issues relevant to vaccine safety and adverse reactions to vaccines.

Matters To Be Discussed: This subcommittee will hold discussions regarding its goals; a report from the Task Force on Safer Childhood Vaccines; a project report on benefit-risk communication curriculum development; and agenda items for the next meeting.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Felecia D. Pearson, Committee Management Specialist, NVPO, CDC, 1600 Clifton Road, NE, M/S D50, Atlanta, Georgia 30333, telephone 404/639–4450.

Dated: December 19, 1997.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–33666 Filed 12–23–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97D–0148]

International Conference on Harmonisation; Guidance on Impurities: Residual Solvents

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is publishing a guidance entitled ''Q3C Impurities: